As exemplified by our recent studies in cardiomyopathy, insertional mutagenesis-based forward genetic screens can be carried out in zebrafish for systematic identification of genetic modifiers, which could lead to the identification of novel therapeutic targets such as dnajb6 and rxra (Ding et al., 2011; Ding et al., 2016; Ma et al., 2020). Here, DNAJB6 is linked to cardiomyopathy.